Company description

Cue Biopharma, Inc. (ticker symbol: CUE) is a clinical-stage biopharmaceutical company that focuses on developing immunomodulatory biologics to treat a wide range of diseases and disorders. The company's approach involves using a proprietary platform called Immuno-STAT (Selective Targeting and Alteration of T cells), which leverages the power of the immune system to fight against diseases. CUE is headquartered in Cambridge, Massachusetts, and was founded in 2015. The company's lead product candidate, CUE-102, is in clinical trials for the treatment of cholangiocarcinoma, a rare form of cancer. Additionally, CUE has a pipeline of other product candidates targeting various forms of cancer, autoimmune disorders, and infectious diseases. The company has a strong team of experienced industry leaders and collaborators, including Merck & Co. and Johnson & Johnson, that aid in the advancement of its cutting-edge therapies. CUE's mission is to improve the lives of patients through innovative and effective treatments, and its dedication to research and development makes it an exciting company to watch in the ever-growing biopharmaceutical industry.